Literature DB >> 7374

Effects of prazosin in patients with hypertension.

P Bolli, A J Wood, F O Simpson.   

Abstract

A double-blind placebo crossover trail (2 periods, each of 6 wk) was carried out in 12 patients. In the first period the patients were randomly allocated to either their individual established dose of prazosin or to the same number of placebo tablets; treatment was reversed after 6 wk. Blood pressure was higher by 17/8 mm Hgin the lying posture and by 24/14 mm Hg in the standing posture during placebo than during prazosin treatment. Standing pulse rate and body weight were higher and plasma renin activity lower during prazosin treatment. Postural hypotension occurring 1 to 2 hr after the first few doses was noted in one third of the patients when they resumed prazosin treatment after the placebo course.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 7374     DOI: 10.1002/cpt1976202138

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-09       Impact factor: 9.546

Review 2.  Antihypertensive pharmacology.

Authors:  J G Gerber; C R Freed; A S Nies
Journal:  West J Med       Date:  1980-05

3.  Clinical pharmacology of prazosin: further discussion.

Authors:  C Barbieri; R Caldara; C Ferrari
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

4.  A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Intraindividual comparison of moxonidine and prazosin in hypertensive patients.

Authors:  V Plänitz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.